| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1371 | 2016 |
| Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ... Cell metabolism 27 (5), 977-987. e4, 2018 | 472 | 2018 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 443 | 2021 |
| An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition L Seguin, S Kato, A Franovic, MF Camargo, J Lesperance, KC Elliott, ... Nature cell biology 16 (5), 457-468, 2014 | 396 | 2014 |
| CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade L Chen, L Diao, Y Yang, X Yi, BL Rodriguez, Y Li, PA Villalobos, ... Cancer discovery 8 (9), 1156-1175, 2018 | 370 | 2018 |
| Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance GN Naumov, MB Nilsson, T Cascone, A Briggs, O Straume, LA Akslen, ... Clinical Cancer Research 15 (10), 3484-3494, 2009 | 365 | 2009 |
| IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy WD Travis, S Dacic, I Wistuba, L Sholl, P Adusumilli, L Bubendorf, P Bunn, ... Journal of Thoracic Oncology 15 (5), 709-740, 2020 | 264 | 2020 |
| Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer JE Chaft, A Rimner, W Weder, CG Azzoli, MG Kris, T Cascone Nature reviews Clinical oncology 18 (9), 547-557, 2021 | 215 | 2021 |
| Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. T Cascone, WN William, A Weissferdt, HY Lin, CH Leung, BW Carter, ... Journal of Clinical Oncology 37 (15_suppl), 8504-8504, 2019 | 203 | 2019 |
| KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling KW Wagner, H Alam, SS Dhar, U Giri, N Li, Y Wei, D Giri, T Cascone, ... The Journal of clinical investigation 123 (12), 5231-5246, 2013 | 187 | 2013 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... Cancer discovery 7 (10), 1088-1097, 2017 | 179 | 2017 |
| Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma T Cascone, MH Herynk, L Xu, Z Du, H Kadara, MB Nilsson, CJ Oborn, ... The Journal of clinical investigation 121 (4), 1313-1328, 2011 | 178 | 2011 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 171 | 2020 |
| Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors MP Morelli, T Cascone, T Troiani, F De Vita, M Orditura, G Laus, ... Annals of Oncology 16, iv61-iv68, 2005 | 159 | 2005 |
| Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy F Ciardiello, T Troiani, R Bianco, M Orditura, F Morgillo, E Martinelli, ... Annals of Oncology 17, vii109-vii114, 2006 | 141 | 2006 |
| Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy F Ciardiello, T Troiani, R Bianco, M Orditura, F Morgillo, E Martinelli, ... Annals of Oncology 17, vii109-vii114, 2006 | 141 | 2006 |
| Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches ER Parra, P Villalobos, C Behrens, M Jiang, A Pataer, SG Swisher, ... Journal for immunotherapy of cancer 6, 1-11, 2018 | 139 | 2018 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 138 | 2021 |
| Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer LA Byers, B Sen, B Saigal, L Diao, J Wang, M Nanjundan, T Cascone, ... Clinical Cancer Research 15 (22), 6852-6861, 2009 | 133 | 2009 |
| Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ... Journal of Thoracic Oncology 15 (9), 1449-1459, 2020 | 130 | 2020 |
